ストックスクリーナーアプリを入手
0.7151
2.30%
0.0161
アフターアワーズ：
.73
0.0149
+2.08%
Cero Therapeutics Holdings Inc (CERO) 最新ニュース
CERo Therapeutics Delays Yearly Report Filing - TipRanks
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors - Nasdaq
CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors - MarketScreener
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors - The Manila Times
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of - GlobeNewswire
Groundbreaking CAR-T Cancer Therapy Advances: FDA Greenlights Dual-Action Trial - Stock Titan
CERo Therapeutics gears up for clinical trial of cancer therapy By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges - Investing.com Australia
CERo Therapeutics gears up for clinical trial of cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Poised to Initiate - GlobeNewswire
FDA Green Light: CERo's Leukemia Drug CER-1236 Advances to Human Trials with Optimized Manufacturing - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Trading 4.6% Higher – Here’s What Happened - Defense World
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish - NewsBreak: Local News & Alerts
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Ca - Asianet Newsable
CERO Flat on Leukemia Drug Developments - Baystreet.ca
CERo Therapeutics partners with UC Davis for AML trial By Investing.com - Investing.com South Africa
CERo Therapeutics partners with UC Davis for AML trial - Investing.com
Restaurant Brands International to Report First Quarter 2025 Results on May 8, 2025 - The Globe and Mail
CERo Therapeutics Announces Manufacturing Agreement with UC Davis Ahead of Phase 1 Clinical Trial for AML - Nasdaq
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study By Investing.com - Investing.com Australia
CERo Therapeutics reports positive preclinical results for cancer treatment By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Understanding CERO’s financial ratios: A beginner’s guide - US Post News
CERo Therapeutics Holdings, Inc. Presents Encouraging - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study - Investing.com
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - The Manila Times
Looking for Exposure to NFLX? Try These Two ETFs - The Globe and Mail
CERo Therapeutics reports positive preclinical results for cancer treatment - Investing.com India
CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation - Nasdaq
Breakthrough: CERo's Novel Cancer Treatment Targets Ovarian Cancer With Zero Toxicity - StockTitan
CERO stock plunges to 52-week low at $1.31 amid market challenges - Investing.com Australia
CERO stock plunges to 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
CERo Therapeutics Holdings, Inc. Announces Progress in - GlobeNewswire
Will This New AML Treatment Strategy Transform Blood Cancer Therapy? CERo Takes Critical Step - StockTitan
CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference - Nasdaq
CERo Therapeutics Holdings, Inc. to Present Data at the - GlobeNewswire
Can CERo's Cancer-Fighting T Cells Transform Ovarian Cancer Treatment? New Data Coming March - StockTitan
3 Companies Buying Back Stock – Why They’re Doubling Down - The Globe and Mail
CERO stock touches 52-week low at $1.52 amid market challenges - Investing.com Canada
CERO stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
10.70%
大文字化:
|
ボリューム (24 時間):